Search Results - "KLUGER, Harriet"

High-Plex Predictive Marker Discovery for Melanoma Immunotherapy-Treated Patients Using Digital Spatial Profiling by Toki, Maria I, Merritt, Christopher R, Wong, Pok Fai, Smithy, James W, Kluger, Harriet M, Syrigos, Konstantinos N, Ong, Giang T, Warren, Sarah E, Beechem, Joseph M, Rimm, David L

“…Protein expression in formalin-fixed, paraffin-embedded tissue is routinely measured by IHC or quantitative fluorescence (QIF) on a handful of markers on a…”
Get full text

Agonistic CD40 Antibodies in Cancer Treatment by Djureinovic, Dijana, Wang, Meina, Kluger, Harriet M

“…CD40 is expressed on a variety of antigen-presenting cells. Stimulation of CD40 results in inflammation by upregulation of other costimulatory molecules,…”
Get full text

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial by Goldberg, Sarah B, Dr, Gettinger, Scott N, MD, Mahajan, Amit, MD, Chiang, Anne C, MD, Herbst, Roy S, Prof, Sznol, Mario, Prof, Tsiouris, Apostolos John, MD, Cohen, Justine, DO, Vortmeyer, Alexander, MD, Jilaveanu, Lucia, MD, Yu, James, MD, Hegde, Upendra, MD, Speaker, Stephanie, BA, Madura, Matthew, BS, Ralabate, Amanda, BSN, Rivera, Angel, MS, Rowen, Elin, MSN, Gerrish, Heather, BSN, Yao, Xiaopan, PhD, Chiang, Veronica, MD, Kluger, Harriet M, Prof

“…Summary Background Immunotherapy targeting the PD-1 axis has activity in several tumour types. We aimed to establish the activity and safety of the PD-1…”
Get full text

Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases? by Colaco, Rovel J, Martin, Pierre, Kluger, Harriet M, Yu, James B, Chiang, Veronica L

“…OBJECT Radiation necrosis (RN), or its imaging equivalent, treatment-related imaging changes (TRIC), is an inflammatory reaction to high-dose radiation in the…”
Get full text

Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery by Qian, Jack M., Yu, James B., Kluger, Harriet M., Chiang, Veronica L. S.

“…BACKGROUND Growing evidence suggests that immunotherapy and radiation therapy can be synergistic in the treatment of cancer. This study was performed to…”
Get full text

Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial by Kluger, Harriet M, Chiang, Veronica, Mahajan, Amit, Zito, Christopher R, Sznol, Mario, Tran, Thuy, Weiss, Sarah A, Cohen, Justine V, Yu, James, Hegde, Upendra, Perrotti, Elizabeth, Anderson, Gail, Ralabate, Amanda, Kluger, Yuval, Wei, Wei, Goldberg, Sarah B, Jilaveanu, Lucia B

“…Pembrolizumab is active in melanoma, but activity in patients with untreated brain metastasis is less established. We present long-term follow-up of…”
Get full text

Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial by Goldberg, Sarah B, Schalper, Kurt A, Gettinger, Scott N, Mahajan, Amit, Herbst, Roy S, Chiang, Anne C, Lilenbaum, Rogerio, Wilson, Frederick H, Omay, Sacit Bulent, Yu, James B, Jilaveanu, Lucia, Tran, Thuy, Pavlik, Kira, Rowen, Elin, Gerrish, Heather, Komlo, Annette, Gupta, Richa, Wyatt, Hailey, Ribeiro, Matthew, Kluger, Yuval, Zhou, Geyu, Wei, Wei, Chiang, Veronica L, Kluger, Harriet M

“…We did a phase 2 trial of pembrolizumab in patients with non-small-cell lung cancer (NSCLC) or melanoma with untreated brain metastases to determine the…”
Get full text

Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas by Krauthammer, Michael, Kong, Yong, Bacchiocchi, Antonella, Evans, Perry, Pornputtapong, Natapol, Wu, Cen, McCusker, Jamie P, Ma, Shuangge, Cheng, Elaine, Straub, Robert, Serin, Merdan, Bosenberg, Marcus, Ariyan, Stephan, Narayan, Deepak, Sznol, Mario, Kluger, Harriet M, Mane, Shrikant, Schlessinger, Joseph, Lifton, Richard P, Halaban, Ruth

“…Ruth Halaban, Michael Krauthammer and colleagues report exome sequencing of 213 melanomas and identify a distinct co-mutation pattern of NF1 with known…”
Get full text

Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma by Sarnaik, Amod A, Hamid, Omid, Khushalani, Nikhil I, Lewis, Karl D, Medina, Theresa, Kluger, Harriet M, Thomas, Sajeve S, Domingo-Musibay, Evidio, Pavlick, Anna C, Whitman, Eric D, Martin-Algarra, Salvador, Corrie, Pippa, Curti, Brendan D, Oláh, Judit, Lutzky, Jose, Weber, Jeffrey S, Larkin, James M G, Shi, Wen, Takamura, Toshimi, Jagasia, Madan, Qin, Harry, Wu, Xiao, Chartier, Cecile, Graf Finckenstein, Friedrich, Fardis, Maria, Kirkwood, John M, Chesney, Jason A

“…Effective treatment options are limited for patients with advanced (metastatic or unresectable) melanoma who progress after immune checkpoint inhibitors and…”
Get full text

Early B cell changes predict autoimmunity following combination immune checkpoint blockade by Das, Rituparna, Bar, Noffar, Ferreira, Michelle, Newman, Aaron M, Zhang, Lin, Bailur, Jithendra Kini, Bacchiocchi, Antonella, Kluger, Harriet, Wei, Wei, Halaban, Ruth, Sznol, Mario, Dhodapkar, Madhav V, Dhodapkar, Kavita M

“…Combination checkpoint blockade (CCB) targeting inhibitory CTLA4 and PD1 receptors holds promise for cancer therapy. Immune-related adverse events (IRAEs)…”
Get full text

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032 by Rubinstein, Jill C, Sznol, Mario, Pavlick, Anna C, Ariyan, Stephan, Cheng, Elaine, Bacchiocchi, Antonella, Kluger, Harriet M, Narayan, Deepak, Halaban, Ruth

“…Activating mutations in BRAF kinase are common in melanomas. Clinical trials with PLX4032, the mutant-BRAF inhibitor, show promising preliminary results in…”
Get full text

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab by TOPALIAN, Suzanne L, SZNOL, Mario, LEMING, Philip D, LIPSON, Evan J, PUZANOV, Igor, SMITH, David C, TAUBE, Janis M, WIGGINTON, Jon M, KOLLIA, Georgia D, GUPTA, Ashok, PARDOLL, Drew M, SOSMAN, Jeffrey A, McDERMOTT, David F, STEPHEN HODI, F, KLUGER, Harriet M, CARVAJAL, Richard D, SHARFMAN, William H, BRAHMER, Julie R, LAWRENCE, Donald P, ATKINS, Michael B, POWDERLY, John D

“…Programmed cell death 1 (PD-1) is an inhibitory receptor expressed by activated T cells that downmodulates effector functions and limits the generation of…”
Get full text

Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma by Wong, Pok Fai, Wei, Wei, Smithy, James W, Acs, Balazs, Toki, Maria I, Blenman, Kim R M, Zelterman, Daniel, Kluger, Harriet M, Rimm, David L

“…Because durable response to programmed cell death 1 (PD-1) inhibition is limited to a subset of melanoma patients, new predictive biomarkers could have…”
Get full text

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma by Nghiem, Paul T, Bhatia, Shailender, Lipson, Evan J, Kudchadkar, Ragini R, Miller, Natalie J, Annamalai, Lakshmanan, Berry, Sneha, Chartash, Elliot K, Daud, Adil, Fling, Steven P, Friedlander, Philip A, Kluger, Harriet M, Kohrt, Holbrook E, Lundgren, Lisa, Margolin, Kim, Mitchell, Alan, Olencki, Thomas, Pardoll, Drew M, Reddy, Sunil A, Shantha, Erica M, Sharfman, William H, Sharon, Elad, Shemanski, Lynn R, Shinohara, Michi M, Sunshine, Joel C, Taube, Janis M, Thompson, John A, Townson, Steven M, Yearley, Jennifer H, Topalian, Suzanne L, Cheever, Martin A

“…Merkel-cell carcinoma is an aggressive neuroendocrine tumor that is poorly responsive to chemotherapy. In a small series of patients, pembrolizumab produced…”
Get full text

Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02) by Diab, Adi, Tannir, Nizar M, Bentebibel, Salah-Eddine, Hwu, Patrick, Papadimitrakopoulou, Vassiliki, Haymaker, Cara, Kluger, Harriet M, Gettinger, Scott N, Sznol, Mario, Tykodi, Scott S, Curti, Brendan D, Tagliaferri, Mary A, Zalevsky, Jonathan, Hannah, Alison L, Hoch, Ute, Aung, Sandra, Fanton, Christie, Rizwan, Ahsan, Iacucci, Ernesto, Liao, Yijie, Bernatchez, Chantale, Hurwitz, Michael E, Cho, Daniel C

“…This single-arm, phase I dose-escalation trial (NCT02983045) evaluated bempegaldesleukin (NKTR-214/BEMPEG), a CD122-preferential IL2 pathway agonist, plus…”
Get more information

Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy by Nghiem, Paul, Bhatia, Shailender, Lipson, Evan J, Sharfman, William H, Kudchadkar, Ragini R, Brohl, Andrew S, Friedlander, Phillip A, Daud, Adil, Kluger, Harriet M, Reddy, Sunil A, Boulmay, Brian C, Riker, Adam I, Burgess, Melissa A, Hanks, Brent A, Olencki, Thomas, Margolin, Kim, Lundgren, Lisa M, Soni, Abha, Ramchurren, Nirasha, Church, Candice, Park, Song Y, Shinohara, Michi M, Salim, Bob, Taube, Janis M, Bird, Steven R, Ibrahim, Nageatte, Fling, Steven P, Homet Moreno, Blanca, Sharon, Elad, Cheever, Martin A, Topalian, Suzanne L

“…Merkel cell carcinoma (MCC) is an aggressive skin cancer often caused by the Merkel cell polyomavirus. Clinical trials of programmed cell death-1 pathway…”
Get full text

Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival: Clinical article by KNISELY, Jonathan P. S, YU, James B, FLANIGAN, Jaclyn, SZNOL, Mario, KLUGER, Harriet M, CHIANG, Veronica L. S

“…Object A prospectively collected cohort of 77 patients who underwent definitive radiosurgery between 2002 and 2010 for melanoma brain metastases was…”
Get full text

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab by McDermott, David F, Drake, Charles G, Sznol, Mario, Choueiri, Toni K, Powderly, John D, Smith, David C, Brahmer, Julie R, Carvajal, Richard D, Hammers, Hans J, Puzanov, Igor, Hodi, F Stephen, Kluger, Harriet M, Topalian, Suzanne L, Pardoll, Drew M, Wigginton, Jon M, Kollia, Georgia D, Gupta, Ashok, McDonald, Dan, Sankar, Vindira, Sosman, Jeffrey A, Atkins, Michael B

“…Blockade of the programmed death-1 inhibitory cell-surface molecule on immune cells using the fully human immunoglobulin G4 antibody nivolumab mediates tumor…”
Get full text

Systemic Immunotherapy for the Treatment of Brain Metastases by Cohen, Justine V, Kluger, Harriet M

Get full text

Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites by Kluger, Harriet M, Zito, Christopher R, Barr, Meaghan L, Baine, Marina K, Chiang, Veronica L S, Sznol, Mario, Rimm, David L, Chen, Lieping, Jilaveanu, Lucia B

“…Programmed death ligand-1 (PD-L1) tumor expression represents a mechanism of immune escape for melanoma cells. Drugs blocking PD-L1 or its receptor have shown…”
Get full text